6933 related articles for article (PubMed ID: 1544709)
1. Differential cytostatic activity of monocyte-derived cytokines against human melanoma cells.
te Velde AA; vd Wiel-v Kemenade E; Figdor CG
Int J Cancer; 1992 Mar; 50(5):746-51. PubMed ID: 1544709
[TBL] [Abstract][Full Text] [Related]
2. Enhancement of human B cell proliferation and differentiation by tumor necrosis factor-alpha and interleukin 1.
Jelinek DF; Lipsky PE
J Immunol; 1987 Nov; 139(9):2970-6. PubMed ID: 3117883
[TBL] [Abstract][Full Text] [Related]
3. A role for the interleukin 1 receptor in the synergistic antitumor effects of human interleukin 1 alpha and etoposide against human melanoma cells.
Usui N; Mimnaugh EG; Sinha BK
Cancer Res; 1991 Feb; 51(3):769-74. PubMed ID: 1824825
[TBL] [Abstract][Full Text] [Related]
4. The incubation of human blood monocytes with tumor necrosis factor-alpha leads to lysis of tumor necrosis factor-sensitive but not resistant tumor cells.
Nii A; Fidler IJ
Lymphokine Res; 1990; 9(2):113-24. PubMed ID: 2338840
[TBL] [Abstract][Full Text] [Related]
5. Synergistic antitumor activity of etoposide and human interleukin-1 alpha against human melanoma cells.
Usui N; Mimnaugh EG; Sinha BK
J Natl Cancer Inst; 1989 Dec; 81(24):1904-9. PubMed ID: 2593167
[TBL] [Abstract][Full Text] [Related]
6. Human tumor necrosis factor potentiates human interleukin 1-mediated rat pancreatic beta-cell cytotoxicity.
Mandrup-Poulsen T; Bendtzen K; Dinarello CA; Nerup J
J Immunol; 1987 Dec; 139(12):4077-82. PubMed ID: 3320203
[TBL] [Abstract][Full Text] [Related]
7. Cytokine-induced procoagulant activity in monocytes and endothelial cells. Further enhancement by cyclosporine.
Carlsen E; Flatmark A; Prydz H
Transplantation; 1988 Oct; 46(4):575-80. PubMed ID: 3051564
[TBL] [Abstract][Full Text] [Related]
8. Species differences in human and rat islet sensitivity to human cytokines. Monoclonal anti-interleukin-1 (IL-1) influences on direct and indirect IL-1-mediated islet effects.
Kawahara DJ; Kenney JS
Cytokine; 1991 Mar; 3(2):117-24. PubMed ID: 1888882
[TBL] [Abstract][Full Text] [Related]
9. Effects of human recombinant tumor necrosis factor-alpha and interleukin 1 on the synthesis of glycosaminoglycan and DNA in cultured rat costal chondrocytes.
Ikebe T; Hirata M; Koga T
J Immunol; 1988 Feb; 140(3):827-31. PubMed ID: 3257505
[TBL] [Abstract][Full Text] [Related]
10. Comparison of the cytostatic and cytolytic activity of tumor necrosis factor-alpha and interleukin 1 alpha in human malignant cell lines.
Herzog TJ; Collin JL
Cytokine; 1992 May; 4(3):214-20. PubMed ID: 1498256
[TBL] [Abstract][Full Text] [Related]
11. Lymphokine-activated effector cells: modulation of activity by cytokines.
Mehta S; Flanagan P; Blackinton D; Wanebo H
Lymphokine Cytokine Res; 1992 Apr; 11(2):73-7. PubMed ID: 1581419
[TBL] [Abstract][Full Text] [Related]
12. Synergistic growth-inhibitory activity of tumour necrosis factor and alpha interferon. Contribution to the monocyte-derived cytostatic activity towards human leukaemia K562 cells.
Nissen-Meyer J; Austgulen R; Espevik T
Scand J Immunol; 1988 Nov; 28(5):627-37. PubMed ID: 3212388
[TBL] [Abstract][Full Text] [Related]
13. Cytostatic and cytotoxic effects of recombinant tumor necrosis factor-alpha on sensitive human melanoma cells in vitro may result in selection of cells with enhanced markers of malignancy.
Zouboulis CC; Schröder K; Garbe C; Krasagakis K; Krüger S; Orfanos CE
J Invest Dermatol; 1990 Dec; 95(6 Suppl):223S-230S. PubMed ID: 2258639
[TBL] [Abstract][Full Text] [Related]
14. Synergistic interactions of interleukin 1, interferon-beta, and tumor necrosis factor in terminally differentiating a mouse myeloid leukemic cell line (M1). Evidence that interferon-beta is an autocrine differentiating factor.
Onozaki K; Urawa H; Tamatani T; Iwamura Y; Hashimoto T; Baba T; Suzuki H; Yamada M; Yamamoto S; Oppenheim JJ
J Immunol; 1988 Jan; 140(1):112-9. PubMed ID: 3275716
[TBL] [Abstract][Full Text] [Related]
15. Tumor necrosis factor and IL-1 associated with plasma membranes of activated human monocytes lyse monokine-sensitive but not monokine-resistant tumor cells whereas viable activated monocytes lyse both.
Ichinose Y; Bakouche O; Tsao JY; Fidler IJ
J Immunol; 1988 Jul; 141(2):512-8. PubMed ID: 3260254
[TBL] [Abstract][Full Text] [Related]
16. Contribution of IL-6 to the antiproliferative effect of IL-1 and tumor necrosis factor on tumor cell lines.
Morinaga Y; Suzuki H; Takatsuki F; Akiyama Y; Taniyama T; Matsushima K; Onozaki K
J Immunol; 1989 Dec; 143(11):3538-42. PubMed ID: 2584706
[TBL] [Abstract][Full Text] [Related]
17. Cytokine regulation of interleukin 6 production by human endothelial cells.
Shalaby MR; Waage A; Espevik T
Cell Immunol; 1989 Jul; 121(2):372-82. PubMed ID: 2500254
[TBL] [Abstract][Full Text] [Related]
18. Human alveolar macrophage and blood monocyte interleukin-6 production.
Kotloff RM; Little J; Elias JA
Am J Respir Cell Mol Biol; 1990 Nov; 3(5):497-505. PubMed ID: 2223104
[TBL] [Abstract][Full Text] [Related]
19. Human interleukin 1 induces interleukin 1 gene expression in human vascular smooth muscle cells.
Warner SJ; Auger KR; Libby P
J Exp Med; 1987 May; 165(5):1316-31. PubMed ID: 3494807
[TBL] [Abstract][Full Text] [Related]
20. T cell lymphokine-induced secretion of cytokines by monocytes from patients with multiple sclerosis.
Maimone D; Reder AT; Gregory S
Cell Immunol; 1993 Jan; 146(1):96-106. PubMed ID: 8425234
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
